January 14, 2021
AmerisourceBergen Announces Quarterly Dividend
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
Pharmaceuticals, Biotechnology and Life Sciences
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today…
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today…